文献速递艾滋病与性传播感染

法国HIV暴露前预防停药的发生率及相关因素

Incidence and factors associated with PrEP discontinuation in France.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

在法国三家医院开展回顾性队列研究,纳入2785名暴露前预防使用者,至2022年12月共653人停药(24%),停药发生率为10.8/100人年;主要停药原因为稳定伴侣关系(32%)和认为治疗不再有用(12%)。年轻、女性、性工作者、报告副作用或≥2种性传播感染与停药相关。

要点

  • 停药发生率10.8/100人年,24%使用者停药。
  • 主要停药原因:稳定伴侣关系32%,认为治疗无用12%。
  • 女性停药风险HR=2.44,副作用HR=2.25,≥2种性传播感染HR=1.87。

核心结论

  • 停药发生率较其他队列观察到的比率相当低,部分停药者仍暴露于HIV风险,强调需要针对性干预以准备和支持停药并限制血清转换风险。

研究设计与样本

  • 2016年1月至2022年6月在法国三家医院开展的回顾性队列研究,纳入研究期间6个月内至少就诊两次的暴露前预防使用者,随访至2022年12月,共2785人(94%男性,5%跨性别者,中位年龄35岁)。

主要发现

  • 至2022年12月,653人停药(24%),停药发生率为10.8/100人年。
  • 停药主要原因为稳定伴侣关系(32%)和认为治疗不再有用(12%)。

临床怎么用

  • 作者认为需要针对性干预以准备和支持暴露前预防停药并限制血清转换风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: HIV pre-exposure prophylaxis (PrEP) is effective in preventing HIV, but some seroconversions occur due to poor adherence or PrEP discontinuation. Our objective was to estimate the incidence of PrEP discontinuation and describe the reasons and factors associated with discontinuations. METHODS: A retrospective cohort was conducted in three French hospitals between January 2016 and June 2022. PrEP users who attended at least twice within 6 months during study period were included and followed up until December 2022. The incidence rate of PrEP discontinuation was estimated by censoring lost to follow up individuals. Factors associated with PrEP discontinuations were identified using a multivariate Cox model. RESULTS: A total of 2785 PrEP users were included, with 94% men and 5% transgender people. Median age was 35 years. By December 2022, 653 users had stopped PrEP (24%). The incidence rate was 10.8 PrEP discontinuations for 100 person-years (PY). The main causes of discontinuation were being in a stable relationship (32%), and not judging the treatment useful anymore (12%). Individuals who discontinued PrEP were younger [<29, HR = 1.45 (1.17-1.80)], and more likely to be women [HR = 2.44 (1.50-3.96)] or sex workers [HR = 1.53 (0.96-2.44)]. They were more likely to report PrEP side effects [HR = 2.25 (1.83-2.77)] or ≥2 sexually transmitted infections [HR = 1.87 (1.53-2.27)] during the last year. CONCLUSION: The incidence of PrEP discontinuations was quite low compared to rates observed in other cohorts. Users who stopped PrEP were sometimes still exposed to HIV, emphasizing the need for targeted interventions to prepare and support PrEP discontinuations and limit seroconversion risk.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Garofoli N, Siguier M, Robineau O, et al. Incidence and factors associated with PrEP discontinuation in France. J Antimicrob Chemother. 2024. PMID: 38758214. doi:10.1093/jac/dkae133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。